Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2026-01-22 @ 8:31 AM
Study NCT ID:
NCT05888103
Status:
COMPLETED
Last Update Posted:
2025-04-20
First Post:
2023-05-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Primary Hypercholesterolemia or Mixed Dyslipidemia | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Inclisiran | View |
| None | LDL-C | View |
| None | monotherapy | View |
| None | atherosclerotic cardiovascular disease | View |
| None | atheroma | View |
| None | Atherosclerosis | View |
| None | lipid | View |
| None | lipid lowering therapy (LLT) | View |
| None | cholesterol | View |
| None | hypercholesteremia | View |
| None | mixed dyslipidemia | View |
| None | TC (total cholesterol) | View |
| None | Apo B | View |
| None | non HDL-C | View |
| None | Lp(a) | View |
| None | PCSK9 | View |
| None | PCSK9 inhibitor | View |
| None | siRNA | View |
| None | low ASCVD risk | View |
| None | moderate ASCVD risk | View |